Skip to content

Molecular Imaging Clinical Study of CD13 and Its Probes in Prostate Cancer

Molecular Imaging Clinical Study of CD13 and Its Probes in Prostate Cancer

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300077817
Enrollment
Unknown
Registered
2023-11-21
Start date
2023-11-21
Completion date
Unknown
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Healthy volunteers or prostate cancer patients:CD13 PET/CT examination

Sponsors

Department of Urology, Xiangya Hospital, Central South University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 78 Years

Inclusion criteria

Inclusion criteria: 1.Age 18-78 years, male; 2.Healthy volunteers or clinical suspicion or pathological confirmation of prostate cancer; 3.No history of other autoimmune diseases, acute infections, acute traumas; 4.Treatment-naïve or minimally treated patients (prior to specific therapies like ADT or novel hormonal therapies); 5.Basic normal cardiac, pulmonary, hepatic, and renal function; 6.Able to cooperate in observing adverse events and treatment efficacy; 7.Written informed consent from patients or their legal representatives; 8.Normal coagulation function.

Exclusion criteria

Exclusion criteria: 1.HIV antibody positive or having other acquired or congenital immunodeficiency diseases or organ transplant history; 2.Fever with a body temperature above 38°C or an active infection that could significantly affect the clinical trial; 3.Uncontrolled hypertension (systolic blood pressure over 160 mmHg or diastolic blood pressure over 100 mmHg); 4.Significant cardiovascular abnormalities (e.g., myocardial infarction, superior vena cava syndrome, severe heart disease of grade 2 or higher before enrollment, or as determined by the investigator, patients at risk of increased ventricular arrhythmia); 5.History of cardiac arrhythmia (multifocal ventricular premature contractions, bigeminy, trigeminy, ventricular congenital long QT syndrome); 6.Tachycardia or uncontrolled atrial fibrillation with symptoms or requiring treatment (CTCAE Grade 3), or asymptomatic sustained tachycardia; 7.Left bundle branch block; 8.Third-degree atrioventricular block or symptomatic sick sinus syndrome.

Design outcomes

Primary

MeasureTime frame
SUVmax;SUVmean;

Countries

China

Contacts

Public ContactYi Cai

Department of Urology, Xiangya Hospital, Central South University

cai-yi@csu.edu.cn+86 136 3731 0713

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026